fluorouracil + triacetyluridine

fluorouracil + triacetyluridine is an investigational or experimental combination of two agents: fluorouracil (5-FU), a cytotoxic antimetabolite widely used as a chemotherapeutic agent for solid tumors, and triacetyluridine (also called uridine triacetate), an oral prodrug of uridine that acts as an antidote for 5-FU-induced toxicity. Fluorouracil inhibits thymidylate synthase, blocking DNA synthesis and causing cytotoxicity in rapidly dividing cells. Triacetyluridine, when administered, is quickly converted to uridine, which enters cells and is converted to uridine triphosphate. This can partially rescue normal tissues by competing with toxic 5-FU metabolites for incorporation into RNA, and partially counteract effects of 5-FU on non-cancerous cells. The combination has been explored in clinical research, primarily to increase the tolerability or efficacy of 5-FU by mitigating its toxicity, allowing for potentially higher dosing or improved safety[1][4][5][6].

Other names

5-fluorouracil + triacetyluridine